Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 1, 2018-- Top-line Results from Phase 2b SADAL Study in DLBCL to be Presented --
NEWTON, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that ten abstracts have been selected for...
-
Oct 29, 2018
NEWTON, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has issued an additional $22.5 million...
-
Oct 26, 2018
NEWTON, Mass., Oct. 26, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Mike Falvey, Executive Vice President,...
-
Oct 11, 2018
NEWTON, Mass., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the pricing of $150 million aggregate...
-
Oct 9, 2018
NEWTON, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it intends to offer, subject to market...
-
Oct 5, 2018-- Application Seeks Accelerated Approval for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma --
NEWTON, Mass., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration...
-
Oct 1, 2018
NEWTON, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of...
-
Sep 25, 2018
NEWTON, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the Company’s management...
-
Sep 20, 2018-- Two Oral Presentations Highlighting Previously Reported Phase 2b STORM Data in Patients with Penta-Refractory Multiple Myeloma and Phase 2b SADAL Data in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma --
NEWTON, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced two oral presentations and one poster...
-
Sep 13, 2018-- Oral Selinexor Achieves 26.2% Overall Response Rate and Duration of Response of 4.4 Months in Overall Study Population; Responses Typically Occurred Within 1 Cycle (4 Weeks) of Treatment --
NEWTON, Mass., Sept. 13, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that updated clinical data from the Phase 2b...